Randomized Clinical Trial to Evaluate the Efficacy of the Permanent Thoracic Catheter (Pleur-X) Towards Pleurodesis in Thoracoscopy in the Treatment of Malignant Pleural Effusion
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Malignant Pleural Effusion
- Sponsor
- Rolf Inderbitzi
- Enrollment
- 234
- Locations
- 1
- Primary Endpoint
- Success rate of the treatment with VPM
- Last Updated
- 7 years ago
Overview
Brief Summary
This is a prospective randomized study whose aim is to compare the efficacy of the permanent thoracic catheter (Pleur-X) versus chemical pleurodesis in videothoracoscopy (VATS) in the treatment of malignant pleural effusion at the first diagnosis.Patients with malignant pleural effusion for whom there is indication of surgery and who agree to participate in the study will be randomized 1: 1 in the Pleur-X arm (arm 1) or in the chemical pleurodesis arm (arm 2).
The arm 1 provides for the installation of a permanent drainage under local anesthesia while the arm 2 provides a pleurodesis with talc in VATS under general anesthesia.
Both procedures are standard of care.
Detailed Description
Before the study procedure the patients will be requested to perform some examination as physical and radiological examination. Patients will also complete questionnaires for quality of life assessment (EORTC QLQ 30) and symptoms (VAS for pain). Patients will then be randomized into one of the two arms. For patients included in arm 1, a permanent drainage (Pleur-X) is provided under local anesthesia performed on an outpatient basis while for patients included in arm 2 a pleurodesis with talc in VATS is planned under general anesthesia. Arm 2 patients will be hospitalized for 5 days. Patients will then be followed up to 3 months after surgery. During this period a medical examination will be required at 1 week, 4 weeks and 3 months after the intervention during which the patient will be asked to complete questionnaires for the evaluation of quality of life (EORTC QLQ 30) and symptoms (VAS for pain ). A chest radiograph will be performed after four weeks to evaluate the primary parameter. Adverse events will be collected throughout the study period.
Investigators
Rolf Inderbitzi
Head of thoracic surgery department
Ente Ospedaliero Cantonale, Bellinzona
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years, \<80 years
- •First diagnosis of malignant pleural effusion
- •Indication to treat the malignant pleural effusion with surgery
- •Informed informed consent
Exclusion Criteria
- •Previous surgeries on the same hemitorace
- •Pregnant women
- •Trapped lung syndrome
- •Patients with estimated life expectancy \< 4-8 weeks
Outcomes
Primary Outcomes
Success rate of the treatment with VPM
Time Frame: 4 weeks
Evaluate the success rate of the treatment with VPM with radiological examination
Secondary Outcomes
- Adverse Event(3 months)
- Quality of live(3 months)
- Pain scale(3 months)